Pharmacokinetics and Pharmacodynamics of Daunoxome in Acute Myeloid Leukemia Patients

At present, it is a general view that the use of various vehicles to carry drugs in the organism is a promising way to enhance their efficacy while reducing their toxicity. The carrier is able to prevent premature drug degradation, inactivation, or elimination from the organism, as well as to abolish or reduce undesirable allergic reactions to drug administration. Retarded release of the drug may prolong its persistence at a necessary level in the organism. One of the most important results expected of the use of drug carriers is their selective delivery to the target cells or organs. In one way or another, carriers may profoundly alter the pharmacokinetics of the drug, diminishing the required dose or a peak concentration, which, in its turn, results in reduced toxicity and increased efficacy. Various macromolecules, microparticles (liposomes), microcapsules, or even cells are suitable for the use as drug vehicles.